Buy Stocks Easy | About Us
September 28, 2020
Buy Stocks Easy | Online Stocks

CLDX


Buy Celldex Therapeutics, Inc. Stock (symbol: CLDX) Easy Online

Company Name: Celldex Therapeutics, Inc.

Symbol: CLDX

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

IPO: 2000

CLDX Current Share Price

Today's CLDX ( Celldex Therapeutics, Inc. ) opening price: $2.2600

Yesterday's CLDX ( Celldex Therapeutics, Inc. ) closing price: $2.2900

Celldex Therapeutics, Inc. Stock ( symbol: CLDX ) Price Chart since IPO (2000):

12 Months Celldex Therapeutics, Inc. Stock ( symbol: CLDX ) Price Chart

Popular Questions about Celldex Therapeutics, Inc. Public Stock ( CLDX )

A: Celldex Therapeutics, Inc. stock symbol (also called stock or share ticker) is CLDX

A: Celldex Therapeutics, Inc. IPO (Initial Public Offering) took place on 2000

A: Celldex Therapeutics, Inc.'s stock (CLDX symbol) price at ther IPO (initial Public Offering) was $2.2600

Q: Is CLDX stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Celldex Therapeutics, Inc. stock (symbol: CLDX) at the beginning of 2019, at the opening share price of $0.5078, with a minimum of $200, by now your shares would be worth $78970 and your profit would be $78770 - SHOW ONLY IF PROFIT.

Buy Celldex Therapeutics, Inc. Stock Easy Online

Celldex Therapeutics, Inc. Stock Ticker Price Chart since IPO:





Celldex Therapeutics, Inc. Stock Price Yesterday



 


Celldex Therapeutics, Inc. Stock Price – Last Week




 


Celldex Therapeutics, Inc. Stock Price – Last Month




 


Celldex Therapeutics, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/18/1948678/0/en/Celldex-Initiates-Phase-1-Study-of-KIT-Inhibitor-CDX-0159.html
                            

                                
Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

                                
                                
CDX-0159 to be studied in chronic idiopathic urticaria after comple...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/619674/celldex-cldx-q3-loss-narrower-than-expected-revenues-miss
                            

                                
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

                                
                                
Celldex (CLDX) reports mixed third-quarter results. Its revenues fa...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/615879/celldex-therapeutics-cldx-reports-q3-loss-lags-revenue-estimates
                            

                                
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

                                
                                
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% a...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/11/1944702/0/en/Celldex-Presents-Promising-Data-from-CDX-0159-and-CDX-527-Programs.html
                            

                                
Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

                                
                                
-CDX-0159 IND accepted; Phase 1 study to start by YE 2019-  -CDX-52...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1943982/0/en/CDX-1140-Demonstrates-Clinical-and-Biological-Activity-in-Patients-with-Advanced-Solid-Tumors-in-Phase-1-Dose-Escalation-Study.html
                            

                                
CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

                                
                                
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for fu...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924048/0/en/Celldex-Therapeutics-Announces-Upcoming-Data-Presentations.html
                            

                                
Celldex Therapeutics Announces Upcoming Data Presentations

                                
                                
HAMPTON, N.J., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Celldex Therapeu...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922864/0/en/Celldex-Therapeutics-to-Present-at-the-Cantor-Global-Healthcare-Conference.html
                            

                                
Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

                                
                                
HAMPTON, N.J., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Celldex Therape...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/18/1948678/0/en/Celldex-Initiates-Phase-1-Study-of-KIT-Inhibitor-CDX-0159.html
                            

                                
Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

                                
                                
CDX-0159 to be studied in chronic idiopathic urticaria after comple...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/619674/celldex-cldx-q3-loss-narrower-than-expected-revenues-miss
                            

                                
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

                                
                                
Celldex (CLDX) reports mixed third-quarter results. Its revenues fa...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/615879/celldex-therapeutics-cldx-reports-q3-loss-lags-revenue-estimates
                            

                                
Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

                                
                                
Celldex (CLDX) delivered earnings and revenue surprises of 10.71% a...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/11/1944702/0/en/Celldex-Presents-Promising-Data-from-CDX-0159-and-CDX-527-Programs.html
                            

                                
Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

                                
                                
-CDX-0159 IND accepted; Phase 1 study to start by YE 2019-  -CDX-52...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/08/1943982/0/en/CDX-1140-Demonstrates-Clinical-and-Biological-Activity-in-Patients-with-Advanced-Solid-Tumors-in-Phase-1-Dose-Escalation-Study.html
                            

                                
CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

                                
                                
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for fu...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1924048/0/en/Celldex-Therapeutics-Announces-Upcoming-Data-Presentations.html
                            

                                
Celldex Therapeutics Announces Upcoming Data Presentations

                                
                                
HAMPTON, N.J., Oct.  02, 2019  (GLOBE NEWSWIRE) -- Celldex Therapeu...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/30/1922864/0/en/Celldex-Therapeutics-to-Present-at-the-Cantor-Global-Healthcare-Conference.html
                            

                                
Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

                                
                                
HAMPTON, N.J., Sept.  30, 2019  (GLOBE NEWSWIRE) -- Celldex Therape...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.